1. Disrupt CAD Study Design
Stable angina, unstable angina or silent ischemia
Moderate and severely calcified, de novo coronary lesions RVD 2.5 – 4.0 mm, stenosis ≥50%,
Lesion length ≤ 32 mm
60 patients enrolled
31 subject OCT sub-study
30 day & 6 months follow-up Core Angiographic & OCT Labs
(Yale University & CRF)
Objective: To assess the safety and performance of the Lithoplasty® System
Primary Safety Endpoint: 30-day MACE (Cardiac death, MI or TVR)
Primary Performance Endpoint: Clinical success (residual stenosis <50%) post-PCI with no evidence of in-hospital MACE.

2. Angiographic Outcomes
Cumulative Frequency Distribution
Diameter Stenosis
68±13% % 50
Cumulative Frequency % 40
13±11% 30 20 10
Pre
Final
MLD (mm)
0.9 ± 0.4
2.6 ± 0.5
Acute Gain (mm) NA
1.7 ± 0.6 1 2
Min Lumen Diameter 3 4
Pre-Procedure
Final Angiography

3. Safety Outcomes Freedom from 30-day MACE: 95%
Final Angiographic Complications
Final N = 60
MACE at 30-­‐days
5.0%
Cardiac Death
0.0%
Non-­‐Q-­‐wave MI
Q-­‐wave MI
TVR
Final N = 60
Residual
0.0%
Abrupt Closure
Slow flow
No reflow
Freedom from 6-Months MACE: 91.5%
Final N = 59
MACE at 6-­‐Months
8.5% (5)
Cardiac Death
3.4% (2)
Non-Q-wave MI
5.1% (3)
Q-wave MI
0.0%
TVR
Results Angiographic core lab adjudicated
& CEC adjudicated

4. Conclusions
Excellent Lithoplasty balloon performance with 100% stent delivery.
High acute gain and low residual stenosis by core lab.
Low CEC adjudicated 30-day MACE rate of 5.0% with minimal vascular complications.
OCT analysis demonstrated heavy calcium burden with substantial luminal acute gain in all groups.
Circumferential calcium fracture confirmed mechanim for lithoplasty validated by OCT analysis.
The Shockwave Medical Coronary Lithoplasty System is investigational and is not available for sale.